期刊文献+

抗肿瘤药物心脏毒性作用机制研究进展 被引量:11

下载PDF
导出
摘要 癌症已经成为全世界人类最大致死原因,发病率与死亡率均呈持续上升趋势。抗肿瘤药物的单独应用或联合放化疗是当前最重要而且极其强大的抗癌工具,但是同时具有一定的潜在心脏毒性。抗肿瘤药物对心脏有多种损害机制及不同临床表现,对患者的生存和预后有着明显影响。近年来临床研究对于抗肿瘤药物的心脏毒性给予高度关注,也取得了一定进展。本文就临床常用抗肿瘤药物对心脏的损害及其发生机制等研究进展进行了综述。
出处 《海南医学》 CAS 2015年第24期3661-3664,共4页 Hainan Medical Journal
基金 国家自然科学基金(编号:81273600)
  • 相关文献

参考文献36

  • 1Word Cancer Report. 2014[EB/OL]. 2014-02-08.http://www.wpro 14wldo vtu short10022014 world _cancer_report/en/.
  • 2Gillespie HS, McGann C J, Wilson BD. Noninvasive diagnosis of ehemother-apy related cardiotoxicity [J]. Curt Cardiol Rev, 2011, 7 (4): 234-244.
  • 3Albini A, Pannesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for eardio-oncology and cardio-oneological preven- tion [J]. J Natl Cancer Inst, 2010, 102(1): 14-25.
  • 4Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Surviv- al of cancer patients diagnosed in 1995-1999. Results and corn- mentary[J]. Eur J Cancer, 2009, 45(6): 931-991.
  • 5OelTmger KC, Mertens AC, Sklar CA, et al. Chronic health condi- tions in adult survivors of childhood cancer [J]. N Engl J Med, 2006, 355(15): 1572-1582.
  • 6Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy [J]. Cardiovasc Toxicol, 2007, 7(2): 61-66.
  • 7Geiger S, Lange V, Suhl P, et al. Anticancer therapy induced cardio- toxicity: review of the literature [J]. Anticancer Drugs, 2010, 21(6): 578-590.
  • 8Jirkovsky E, Popelova O, Krivakova-Stankova P, et al. Chronic an- thracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondri- al biogenesis pathways [J]..l Pharmacol Exp Ther, 2012, 343(2): 468-478.
  • 9Swain SM, Whaley FS, Ewer MS. Congestive heart failure in pa- tients treated with doxombicin: a retrospective analysis of three tri- als [J]. Cancer, 2003, 97(11): 2869-2879.
  • 10Keefe DL. Anthracycline-induced cardiomyopathy [J]. Semin in On- col, 2001, 28(4 suppl 12): 2-7.

二级参考文献64

  • 1冯洁.介绍几种抗肿瘤的靶向新药[J].中国药师,2006,9(2):176-178. 被引量:7
  • 2Jemal A, Murray T, Samuels A, et al. Cancer stautistics 2003[J]. CA Cancer J Clin, 2003,53(1):5-26.
  • 3Giordano A, Rustum Y M, Wenner C E. Cell cycle;molecular targets for diagnosis and therapy;tumor suppressor genes and cell cycle progression in cancer[J]. J Cell Biochem, 1998,70(1):1-7.
  • 4Colombat P, Sales G, Borusse N, et al. Rituximab(anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden; clinical and molecular evaluation[J]. Blood, 2001,97(1):101-106.
  • 5Coifier B. Effective immunochemotherapy for aggressive non-Hodgkin' s lymphoma[J]. Semin Oncol, 2004,31(1 Suppl 2):7-11.
  • 6Yarden Y.The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities[J]. Eur J Cancer, 2001,37(Suppl):3-8.
  • 7Stever S H. For the herceptin multinatinonal investigator study group. Overview of the trastuzuanrb(Hecreptin) in HER-2 mnoclonal antibody clinical program in HER2-overexpressing metastatic berast cacner[J]. Semin Onclol, 1999,26:12-71.
  • 8Pegram M D, Slamon D J, Dennis J S, et al. Combination therapy with trastuzuanrb (Hecreptin) and cispaltin for chemoresist intantmetastatci breast cancer; evidence for receptor-enhanced chemosensitive[J]. Semin Oncol, 1999,26:82-89.
  • 9Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab[J]. Eur J Cancer, 2001,37(4):16-22.
  • 10Nygren P, Sorbye H O, Sterlund P, et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an acts oncologica expert report[J]. Acta Oncol, 2005,44(3):203-217.

共引文献24

同被引文献108

引证文献11

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部